Peptide Vaccine Shows Clinical Benefit in Glioblastoma

A personalized peptide vaccination shows clinical benefit for human leukocyte antigen-A24-positive glioblastoma multiforme patients refractory to temozolomide-based therapy.

Source: CancerNetwork - June 28, 2017 Category: Cancer & Oncology Authors: Mark L. Fuerst Tags: Brain Tumors News Source Type: news